What's the Problem?
Globally, the strategy to deal with major disease burdens is shifting from a therapeutic to diagnostic mode, with an improvement in cost and efficacy of treatment. Moreover, the spread of infectious diseases, the management of medical emergencies and the benefits of decentralized care underline the need for rapid, cost-effective, point-of-care (POC) diagnostic devices. Microfluidics technologies are ideally suited for that demand, but surprisingly few lab-on-a-chip-based diagnostic tests have been successfully introduced into the market. This applies also for the disorders related to bleeding and thrombosis, where several tests offer a specific, but incomplete, picture of hemostasis, prompting a desire for an integrated test of global hemostasis.
How are they Solving it?
The point-of-care diagnostics segment offers huge potential for microfluidics. But there is a need to bridge the gap between basic-science innovation and commercialization. MZP develops point-of-care diagnostic devices based on microfluidics, with a focus in usefulness, simplicity, robustness and scalability. MZP have successfully applied this approach in a portable, low-cost, point-of-care viscoelastic coagulation analyzer, intended for the management of bleeding in critical care patients. Furthermore, they plan to apply the advantages of microfluidics, such as small volume requirements, portability, integration, multiplexed screening and flow based analysis in the development of a flow-based global hemostasis evaluation platform. Finally, their vision is to develop and integrate a portfolio of standardized microfluidic modules that will allow efficient and robust implementation of new POC diagnostic devices.